Board of Directors
Joe McMahon is the President and CEO of Bioventure Partners, a growth advisory and investment firm, serving high-impact, technology driven organizations. Previously, Joe was President and CEO at KBI Biopharma, a biopharmaceutical CDMO, from 2002 until 2016. Before KBI, Joe was a Vice President with Covance Biotechnology Services, a biopharmaceutical CDMO, from 1996 until 2002.
Sue Mahony, Ph.D., MBA
Sue Mahony, Ph.D., is a corporate director for Horizon Therapeutics Inc., Assembly Biosciences Inc., Zymeworks Inc., Vifor Pharma, and Cereius Inc. Sue spent 18 years at Eli Lilly and Company, leading organizations in commercial, product development, human resources and general management in Europe, the United States, Canada, Japan and China. Sue earned her BS in Pharmacy, her Doctorate of Philosophy in Pharmacy, and an honorary doctorate from the University of Aston, UK. She also received her MA in Business Administration from the London School of Business.
Michael Biron, MBA, is the CEO, co-founder and Chairman of the Board of Altis Biosystems. He is a former U.S. Army Officer, with experience in project management, logistics, and leadership development. Prior to the military, Michael spent several years as a top sales representative. He also worked in project management and was responsible for overseeing a variety of projects valued up to $26M. Michael has a Bachelor’s degree from Penn State and an MBA from UNC Kenan-Flagler Business School, with a concentration in entrepreneurship.
Christopher Sims, MD
Dr. Christopher Sims, MD, is the President and a co-founder of Altis Biosystems and is a Professor at the University of Washington. He holds a BS in Physical Sciences (Chemistry) from Auburn University and an MD from Johns Hopkins University. He completed a medical residency at the Beth Israel Hospital, Harvard University, and postdoctoral clinical fellowships in medicine and in rheumatology at Stanford University Hospital. His postdoctoral research work was in Physiology and Biophysics at the University of California, Irvine where he remained on faculty until his move to UNC-Chapel Hill in 2007. His current research is aimed at the development of cell-based assays and microfabricated technologies for clinical and biomedical applications, particularly in the field of stem cell research. Dr. Sims has been the scientific co-founder of three prior companies: Cell Biosciences (currently Protein Simple); Intellego, Inc.; and Cell Microsystems, Inc.
Sam Franklin, MD
Sam Franklin, MD, is a private investor and member of VentureSouth, a Greenville, South Carolina group of angel investors located across the Southeastern United States. He previously worked as a clinical nephrologist and medical entrepreneur in Charleston, South Carolina. Sam attended medical school at UNC Chapel Hill and postgraduate training at Washington University in St Louis.
Dave Morris is a pharmaceutical scientist with over 15 years of experience leading multi-disciplinary international line and matrixed research groups in the US, UK, and Europe, spanning target identification to clinical candidate selection. Over the course of his career at GlaxoSmithKline, Dave managed teams that were responsible for target and hit discovery, lead optimization, technology development and implementation. After 20 plus years in the pharmaceutical industry, Dave founded an early stage drug discovery and technology evaluation consultancy, Collaborative Pharma Consulting, LLC. He obtained his Ph.D. in cell biology from the University of Liverpool in the UK.
Ben Scruggs, Ph.D.
Ben Scruggs, Ph.D., is an Associate at Hatteras Venture Partners in Durham, NC. He supports the firm’s new portfolio company diligence, existing portfolio strategy, and overall operations. Prior to joining Hatteras in 2016, Ben was a postdoctoral fellow in the Epigenetics and Stem Cell Biology Laboratory at the National Institute of Environmental Health Sciences. He has performed research in the fields of genomics, metabolism, RNA biology, and transcription regulation. Ben received his B.E. in biomedical engineering from Vanderbilt University and a Ph.D. in molecular cell biology from Washington University in St. Louis.
Scott has over 35 years of venture capital and operating experience, primarily working with early stage and growth companies. He is currently a Venture Partner with two early stage venture capital firms in the RTP, NC, The Aurora Funds, Inc. (Aurora) and Cofounders Capital. In addition, Scott is a Professor of the Practice at the Kenan Flagler Business School at the University of North Carolina – Chapel Hill where he teaches several classes in the entrepreneurship area.
Nancy Allbritton, Ph.D., MD
Nancy Allbritton, Ph.D., MD, is a Co-Founder of Altis Biosystems. Dr. Allbritton’s research and commercialization efforts are directed to the development of new technologies by bringing to bear methods from engineering, chemistry, physics, and biology to address biomedical problems. Currently Dean of the Engineering School at the University of Washington, Nancy was the Kenan Professor and Chair of the Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill (UNC) and North Carolina State University (NC State). She obtained her Ph.D. in Medical Physics/Medical Engineering from the Massachusetts Institute of Technology, and her M.D. from the Johns Hopkins University.
Yuli Wang, Ph.D.
Yuli Wang, Ph.D., is a Co-Founder of Altis Biosystems, where he works with Dr. Allbritton and Dr. Sims in developing new technologies to address important biomedical problems. He has experience in entrepreneurship development activities and obtained his Ph.D. from University of California, Irvine.